Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 89,160 $ 213,841
Operating expenses:    
Cost of implants and other costs 35,986 15,279
Research and development 891,063 1,459,458
Selling, general and administrative 2,875,119 3,409,649
Impairment of intellectual property 47,980 0
Depreciation and amortization 26,808 27,450
Total operating expenses 3,876,956 4,911,836
Loss from operations (3,787,796) (4,697,995)
Other income (expenses):    
Interest expense - related parties (692,586) (935,806)
Interest expense, net (194,041) (150,969)
Loss on settlement of debt (34,338) (198,939)
Loss on contingency 0 (322,000)
Grant income 932,996 1,789,496
Other miscellaneous income 5,275 139,381
Total other income, net 17,306 321,163
Loss before provision for income taxes (3,770,490) (4,376,832)
Income taxes 0 0
Net loss (3,770,490) (4,376,832)
Non-controlling interest 3,577 7,419
Net loss attributable to BioCorRx Inc. $ (3,766,913) $ (4,369,413)
Net loss per common share, basic and diluted $ (0.45) $ (0.61)
Weighted average number of common shares outstanding, basic and diluted 8,344,079 7,198,312